Inhibition of leukemic stem cells by PP2A activating agents

US9220706B2 · kind B2 · utility

Assignees

• NATIONAL INSTITUTES OF HEALTH (NIH) · US
• U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) · US
• THE UNITED STATES OF AMERICA NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR) · US

Inventors

• Danilo Perrotti · Dublin, US
• Paolo Neviani · Columbus, US

Key dates

• Filing date: May 31, 2013
• Grant date: Dec 29, 2015
• Expiry date: May 31, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/137
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of inhibiting the growth of leukemic hematopoietic stem cells in a subject with leukemia is described. The method includes administering a therapeutically effective amount of a composition including a compound of formula I: I wherein R1 is independently selected from hydrogen and methyl; R2 is selected from the group consisting of 4,8-dimethyl-non-1-enyl, 4,8-dimethyl-nonyl, non-1-enyl, and nonanyl groups; X is a carboxyl, phosphonic, or sulfonic moiety, and n is an integer from 1 to 6, or a compound of Formula II: II wherein R1 is a C6-C12 alkyl or C6-C12 alkoxy group; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; and R3 is an alkyl or cycloalkyl group; or a pharmaceutically acceptable salt thereof.